Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2014

01-02-2014 | Original Article

Test–retest reliability of [11C]AZ10419369 binding to 5-HT1B receptors in human brain

Authors: Magdalena Nord, Sjoerd J. Finnema, Martin Schain, Christer Halldin, Lars Farde

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2014

Login to get access

Abstract

Purpose

[11C]AZ10419369 is a recently developed 5-HT1B receptor radioligand that is sensitive to changes in endogenous serotonin concentrations in the primate brain. Thus, [11C] AZ10419369 may serve as a useful tool in clinical studies of the pathophysiology and pharmacological treatment of diseases related to the serotonin system, such as depression and anxiety disorders. The aim of this study was to evaluate the test–retest reliability of [11C]AZ10419369.

Methods

Eight men were examined with PET and [11C] AZ10419369 twice on the same day. The binding potentials (BPND) of [11C]AZ10419369 in selected serotonergic projection areas and in the raphe nuclei (RN) were determined using the simplified reference tissue model, and for comparison also using a wavelet-aided parametric imaging approach. The BPND values obtained from the first and second PET scans were compared by means of descriptive statistics, difference, absolute variability and intraclass correlation coefficient.

Results

Similar BPND values were obtained with the two methods. The absolute mean differences in BPND between PET 1 and PET 2 were less than 3 % in all serotonergic projection regions. Absolute variabilities were low in cortical regions (5 – 7 %), low to moderate (7 – 14 %) in subcortical regions, but higher (20 %) in the RN.

Conclusion

The BPND of [11C]AZ10419369 is highly reproducible in cortical regions and satisfactory in subcortical projection areas. The variability in the RN is higher. Thus larger sample sizes or larger divergences are required to assess a potential difference between subjects or between experimental conditions in this region.
Appendix
Available only for authorised users
Literature
1.
Sari Y. Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004;28:565–82.PubMedCrossRef
2.
Ruf BM, Bhagwagar Z. The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets. 2009;10:1118–38.PubMedCrossRef
3.
Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson’s disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol. 2002;9 Suppl 3:1–6.PubMedCrossRef
4.
Varnas K, Jucaite A, McCarthy DJ, Stenkrona P, Nord M, Halldin C, et al. A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers. Cephalalgia. 2013;33:853–60.PubMedCrossRef
5.
Varnas K, Hall H, Bonaventure P, Sedvall G. Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [3H]GR 125743. Brain Res. 2001;915:47–57.PubMedCrossRef
6.
Varnas K, Hurd YL, Hall H. Regional expression of 5-HT1B receptor mRNA in the human brain. Synapse. 2005;56:21–8.PubMedCrossRef
7.
Adell A, Celada P, Artigas F. The role of 5-HT1B receptors in the regulation of serotonin cell firing and release in the rat brain. J Neurochem. 2001;79:172–82.PubMedCrossRef
8.
Varnas K, Nyberg S, Halldin C, Varrone A, Takano A, Karlsson P, et al. Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow Metab. 2011;31:113–23.PubMedCrossRef
9.
Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnas K, et al. [11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage. 2008;41:1075–85.PubMedCrossRef
10.
Andersson JD, Pierson ME, Finnema SJ, Gulyas B, Heys R, Elmore CS, et al. Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. Nucl Med Biol. 2011;38:261–72.PubMedCrossRef
11.
Finnema SJ, Varrone A, Hwang TJ, Gulyas B, Pierson ME, Halldin C, et al. Fenfluramine-induced serotonin release decreases [11C]AZ10419369 binding to 5-HT(1B)-receptors in the primate brain. Synapse. 2010;64:573–7.PubMedCrossRef
12.
Nord M, Finnema SJ, Halldin C, Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int J Neuropsychopharmacol. 2013;16:1577–86.PubMedCrossRef
13.
Finnema SJ, Varrone A, Hwang TJ, Halldin C, Farde L. Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [11C]AZ10419369 using an equilibrium approach. J Cereb Blood Flow Metab. 2012;32:685–95.PubMedCrossRef
14.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;20(59 Suppl):22–33; quiz 4–57.PubMed
15.
Derry C, Benjamin C, Bladin P, le Bars D, Tochon-Danguy H, Berkovic SF, et al. Increased serotonin receptor availability in human sleep: evidence from an [18F]MPPF PET study in narcolepsy. Neuroimage. 2006;30:341–8.PubMedCrossRef
16.
Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36:1639–50.PubMedCrossRef
17.
Schain M, Toth M, Cselenyi Z, Stenkrona P, Halldin C, Farde L, et al. Quantification of serotonin transporter availability with [11C] MADAM – a comparison between the ECAT HRRT and HR systems. Neuroimage. 2012;60:800–7.PubMedCrossRef
18.
Bonaventure P, Schotte A, Cras P, Leysen JE. Autoradiographic mapping of 5-HT1B- and 5-HT1D receptors in human brain using [3H]alniditan, a new radioligand. Receptors Channels. 1997;5:225–30.PubMed
19.
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.PubMedCrossRef
20.
Cselenyi Z, Olsson H, Farde L, Gulyas B. Wavelet-aided parametric mapping of cerebral dopamine D2 receptors using the high affinity PET radioligand [11C]FLB 457. Neuroimage. 2002;17:47–60.PubMedCrossRef
21.
McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30–46.CrossRef
22.
Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–8.PubMedCrossRef
23.
Alakurtti K, Aalto S, Johansson JJ, Nagren K, Tuokkola T, Oikonen V, et al. Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography. J Cereb Blood Flow Metab. 2011;31:155–65.PubMedCrossRef
24.
Lundberg J, Halldin C, Farde L. Measurement of serotonin transporter binding with PET and [11C]MADAM: a test-retest reproducibility study. Synapse. 2006;60:256–63.PubMedCrossRef
25.
Hirvonen J, Kajander J, Allonen T, Oikonen V, Nagren K, Hietala J. Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-(11)C]WAY-100635 – considerations on the validity of cerebellum as a reference region. J Cereb Blood Flow Metab. 2007;27:185–95.PubMedCrossRef
26.
Jovanovic H, Cerin A, Karlsson P, Lundberg J, Halldin C, Nordstrom AL. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res. 2006;148:185–93.PubMedCrossRef
27.
Paterson LM, Kornum BR, Nutt DJ, Pike VW, Knudsen GM. 5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev. 2013;33:54–111.PubMedCrossRef
28.
Selvaraj S, Turkheimer F, Rosso L, Faulkner P, Mouchlianitis E, Roiser JP, et al. Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. Mol Psychiatry. 2012;17:1254–60.PubMedCrossRef
Metadata
Title
Test–retest reliability of [11C]AZ10419369 binding to 5-HT1B receptors in human brain
Authors
Magdalena Nord
Sjoerd J. Finnema
Martin Schain
Christer Halldin
Lars Farde
Publication date
01-02-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2529-1

Other articles of this Issue 2/2014

European Journal of Nuclear Medicine and Molecular Imaging 2/2014 Go to the issue

Editorial

Good clinical practice in pulmonary embolism diagnosis: where do we stand today?

Original Article

Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT

Image of the Month

Isolated cerebellar metastasis from prostate adenocarcinoma diagnosed by 18F-fluorocholine PET/CT: a rare but not impossible complication

Editorial

Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine

Original Article

The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma

Original Article

Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients